# Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

> **NCT07430956** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 2628 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** REGN7508
- **DRUG:** REGN9933
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07430956
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-03
- **Primary completion:** 2029-03-28
- **Final completion:** 2029-06-26
- **Target enrollment:** 2628 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07430956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07430956, "Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07430956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*